Saturday, July 31, 2021 10:50:38 AM
The stock has a history of explosive moves running to $0.175 earlier this year after the Company and its subsidiary KLS entered into an agreement with Oncology Pharma, Inc. whereby Regen granted to Licensee an exclusive right and license for the development and commercialization of certain intellectual property for the treatment in humans of pancreatic cancer for a term of fifteen years from April 7, 2021.
Recent RGBP News
- Regen BioPharma Update on Orphan Drug Application for HemaXellerate Will Be Presented At Emerging Growth Conference on September 24, 2025 • GlobeNewswire Inc. • 09/23/2025 12:00:00 PM
- Regen BioPharma Prepares Response For FDA Regarding Its Orphan Drug Application for HemaXellerate • GlobeNewswire Inc. • 09/16/2025 12:00:00 PM
Exxe Group Advances Platform Strategy and Share Structure Reduction Following Strategic Meetings • AXXA • Mar 11, 2026 1:03 PM
DRCR Pushes Forward With Implementation of 2026 Business Plan • DRCR • Mar 11, 2026 12:26 PM
Record Gold Prices Reshape Opportunities for Emerging Producers • LFLR • Mar 11, 2026 9:00 AM
C2 Blockchain Reports 803 Million DOG (Bitcoin) Holdings Following Strategic Accumulation of Bitcoin-Native Digital Assets • CBLO • Mar 10, 2026 8:00 AM
RENI Completes Due Diligence on Target Acquisition; Confirms Strong Asset Base and Operational Performance • RENI • Mar 5, 2026 10:15 AM
BlackStar Engages in Talks with U.S. Senate Banking Committee Team Covering the Digital Asset Market Clarity Act • BEGI • Mar 4, 2026 4:47 PM
